JNJ Price Prediction Next Week
Based on the provided data and technical analysis, here's the prediction for JNJ's stock price next week:
Technical Analysis
- Current price: $144.62
- Fibonacci support levels: $141.66, $139.84, $136.90
- Fibonacci resistance levels: $147.54, $149.36, $152.30
- RSI(14) at 52.32 indicates neutral momentum
- MACD at -0.90 shows bearish momentum in the short term
News Impact Analysis
- JNJ will report Q4 earnings on January 22, 2025. Analysts expect EPS of $2.00, down 12.7% YoY.
- The company faces headwinds from Stelara biosimilar competition in 2025, which could impact revenues significantly.
- Recent temporary pause of Varipulse heart device due to safety concerns could affect MedTech segment performance.
- Positive catalysts include potential FDA approval for Nipocalimab and growing market share for Carvykti and Spravato.
Price Prediction Based on technical indicators and upcoming earnings:
- Short-term target: $143.50 (key support level)
- If earnings disappoint, price could test lower support at $141.66
- If earnings beat expectations, resistance at $147.54 could be tested
Trading Recommendation SELL with target price of $143.50 Rationale:
- Bearish MACD indicates downward momentum
- Key support at $143.50 showing weakness
- Upcoming earnings risks and Stelara competition concerns
- Technical resistance around $147.54 likely to cap upside
JNJ Similar Chart Price Prediction
The price of JNJ is predicted to go up -6.75%, based on the high correlation periods with ZYME. The similarity of these two price pattern on the periods is 92.81%.
JNJ
ZYME
Down: -6.75%Similarity: 92.81%
JNJ Revenue Forecast
JNJ EPS Forecast
JNJ FAQs
What is bull’s view on JNJ?
What is bear's view on JNJ?
What is JNJ revenue forecast for next quarter？
What is JNJ eps forecast for next quarter？
JNJ VS S&P500
The majority of J&J's near-term patent losses are for products that are hard to manufacture, which should reduce the intensity of generic competition.
Diverse healthcare segments help insulate J&J from downturns in the overall economy, offering a defensive growth opportunity with a steady and likely growing dividend.
Several of J&J's key next-generation pipeline drugs are specialty drugs that tend to carry strong pricing power as well as lower regulatory hurdles for approval.
JNJ Analyst's Forecast
Tim Anderson
B of A Securities
Hold
Price Target
$166 → $160
Upside
+8.82%
BofA analyst Tim Anderson lowered the firm's price target on Johnson & Johnson to $160 from $166 and keeps a Neutral rating on the shares. The firm's revised target, based on a sum-of-the-parts valuation methodology, reflects new, lower 2025 EPS estimates, the analyst tells investors in a Q4 preview note.
Joanne Wuensch
Citigroup
Strong Buy
Price Target
$185 → $175
Upside
+19.34%
Tim Anderson
B of A Securities
Hold
Price Target
$166
Upside
+11.24%